The FDA has deemed marketing materials touting Latisse, the newly released prescription eyelash thickener marketed by Allergan, as “misleading.” The FDA stated that Latisse ads omit and minimize risks associated with the product, such as redness and eye color changes. According to Reuters, the FDA has asked Allergan to immediately stop using the materials. Dow Jones has explained that the eye infection, bacterial keratitis, can cause blindness.

Sirion Therapeutics has received the US FDA has approved its NDA for Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% as a treatment for acute herpetic keratitis (dendritic ulcers). The FDA approval was based on the results of clinical trials conducted by Laboratoires Thea of France in Europe, Asia and Africa that compared the efficacy and tolerability of Zirgan to acyclovir ophthalmic ointment 3% in patients with herpetic keratitis.

A study conducted by a team lead by Dr. John Bullock of Wright State University’s Boonshoft School of Medicine found that improper temperature control of Bausch & Lomb’s ReNu with MoistureLoc may have contributed to the outbreak of a fungal infection of the cornea in 2008. The study was published in the peer-reviewed Archives of Ophthalmology.